Antifungals In Eye Infections: Drugs And Routes Of Administration

Treatment of fungal eye infections represents a challenge to the ophthalmology practice. For an adequate therapeutic response, besides correct drug choice, it is necessary an effectively administration. This script gathers information about the major antifungal drugs used in eye infections, their concentrations and main administration routes.722132141Leber, T.H., Keratomycosis aspergillina als ursache von hypopyonkeratites (1879) Graefes Ach Clin Exp Ophthalmol, 25, pp. 285-301Alfonso, E.C.G.A., Miller, D., Fungal keratitis (2011) Cornea: fundamentals, diagnosis and management, , In: Krachmer JH, Mannis MJ, Holland EJ, editors.3rd ed. New York: Mosby ElsevierJones, D., Diagnosis and management of fungal keratitis Duane's clinical ophthalmology, p. 2004. , In: Tasman W, Jaeger EA, editors.Philadelphia: Lippincott Williams & WilkinsBennett, J., Agentes antimicrobianos, agentes antifúngicos (2007) As bases farmacológicas da terapêutica, pp. 1103-1117. , In: Brunton L, editor Goodman & Gilman:11a ed. Rio de Janeiro: McGraw-HillReddy, P.R., Reddy, P.S., Reddy, A.R., Saboo, N.K., A comparative evaluation of Nystatin, Amphotericin-B and Miconazole in keratomycosis (1982) Indian J Ophthalmol, 30 (4), pp. 249-250Oliveira, P.R., Resende, S.M., Oliveira, F.C., Oliveira, A.C., Ceratite fúngica (2001) Arq Bras Oftalmol, 64 (1), pp. 75-79Filippin, F.B., Souza, L.C., Eficiência terapêutica das formulações lipídicas de anfotericina B (2006) RBCF Rev Bras Ciênc Farm, 42 (2), pp. 167-194Martinez, R., Atualização no uso de agentes antifúngicos (2006) J Bras Pneumol, 32 (5), pp. 449-460Gallis, H.A., Drew, R.H., Pickard, W.W., Amphotericin B: 30 years of clinical experience (1990) Rev Infect Dis, 12 (2), pp. 308-329Kaur, I.P., Rana, C., Singh, H., Development of effective ocular preparations of antifungal agents (2008) J Ocul Pharmacol Ther, 24 (5), pp. 481-493. , ReviewKhoo, S.H., Bond, J., Denning, D.W., Administering amphotericin B-a practical approach (1994) J Antimicrob Chemother, 33 (2), pp. 203-213Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A.L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Perfect, J., Caspofungin Invasive Candidiasis Study Group.Comparison of caspofungin and amphotericin B for invasive candidiasis (2002) N Engl J Med, 347 (25), pp. 2020- 9. , Comment in N Engl J Med. 2002;347(25):2070-2. ACP J Club. 2003;139(1):15. N Engl J Med. 2003;348(13):1287-8author reply 1287-8Shirley, S.F., Little, J.R., Immunopotentiating effects of amphotericin B (1979) I.Enhanced contact sensitivity in mice. J Immunol., 123 (6), pp. 2878-2882Shirley, S.F., Little, J.R., Immunopotentiating effects of amphotericin B (1979) II Enhanced in vitro proliferative responses of murine lymphocytes. J Immunol., 123 (6), pp. 2883-2889Green, W.R., Bennett, J.E., Goos, R.D., Ocular penetration of amphotericin B: a report of laboratory studies and a case report of postsurgical cephalosporium endophthalmitis (1965) Arch Ophthalmol, 73, pp. 769-775Goldblum, D., Frueh, B.E., Zimmerli, S., Böhnke, M., Treatment of postkeratitis fusarium endophthalmitis with amphotericin B lipid complex (2000) Cornea, 19 (6), pp. 853-856O'Day, D.M., Head, W.S., Robinson, R.D., Stern, W.H., Freeman, J.M., Intraocular penetration of systemically administered antifungal agents (1985) Curr Eye Res, 4 (2), pp. 131-134. , Erratum in: Curr Eye Res 1986;5(7):547Qu, L., Li, L., Xie, H., Corneal and aqueous humor concentrations of amphotericin B using three different routes of administration in a rabbit model (2010) Ophthalmic Res, 43 (3), pp. 153-158Pleyer, U., Grammer, J., Pleyer, J.H., Kosmidis, P., Friess, D., Schmidt, K.H., Thiel, H.J., Studies with local administration of liposome incorporated amphotericin (1995) Amphotericin B-bioavailability in the cornea Ophthalmologe, 92 (4), pp. 469-475. , GermanO'Day, D.M., Head, W.S., Robinson, R.D., Clanton, J.A., Corneal penetration of topical amphotericin B and natamycin (1986) Curr Eye Res, 5 (11), pp. 877-882O'Day, D.M., Ray, W.A., Head, W.S., Robinson, R.D., Influence of the corneal epithelium on the efficacy of topical antifungal agents (1984) Invest Ophthalmol Vis Sci, 25 (7), pp. 855-859Hirose, H., Terasaki, H., Awaya, S., Yasuma, T., Treatment of fungal corneal ulcers with amphotericin B ointment (1997) Am J Ophthalmol, 124 (6), pp. 836-838Wood, T.O., Williford, W., Treatmen of keratomycosis with amphotericin B 015% (1976) Am J Ophthalmol., 81 (6), pp. 847-849O'Day, D.M., Selection of appropriate antifungal therapy (1987) Cornea, 6 (4), pp. 238-245. , ReviewO'Day, D.M., Ray, W.A., Robinson, R.D., Head, W.S., Williams, T.E., Differences in response in vivo to amphotericin B among Candida albicans strains (1991) Invest Ophthalmol Vis Sci, 32 (5), pp. 1569-1572Garcia-Valenzuela, E., Song, C.D., Intracorneal injection of amphothericin B for recurrent fungal keratitis and endophthalmitis (2005) Arch Ophthalmol, 123 (12), pp. 1721-1723Kermani, N.K., Aggarwal, S.P., Isolated post-operative Aspergillus niger endophthalmitis (2000) Eye (Lond), 14 (PART 1), pp. 114-116Yoon, K.C., Jeong, I.Y., Im, S.K., Chae, H.J., Yang, S.Y., Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis (2007) Cornea, 26 (7), pp. 814-818Kaushik, S., Ram, J., Brar, G.S., Jain, A.K., Chakraborti, A., Gupta, A., Intracameral amphotericin B: initial experience in severe keratomycosis (2001) Cornea, 20 (7), pp. 715-719Kuriakose, T., Kothari, M., Paul, P., Jacob, P., Thomas, R., Intracameral amphotericin B injection in the management of deep keratomycosis (2002) Cornea, 21 (7), pp. 653-656Yilmaz, S., Ture, M., Maden, A., Efficacy of intracameral amphotericin B injection in the management of refractory keratomycosis and endophthalmitis (2007) Cornea, 26 (4), pp. 398-402Perraut, L.E., Perraut, L.E., Bleiman, B., Lyons, J., Successful treatment of Candida albicans endophthalmitis with intravitreal amphotericin B (1981) Arch Ophthalmol, 99 (9), pp. 1565-1567Serracarbassa, P.D., Peyman, G.A., Liang, C., Calixto, N., Nair, M.G., Toxicity and efficacy of intravitreal injection of spartanamicin B in the treatment of Candida endophthalmitis (1998) Int Ophthalmol, 22 (1), pp. 53-58Mascaro, V.L.D.M., Höfling-Lima, A.L., Gompertz, O.F., Yu, M.C.Z., Matta, D.A., Colombo, A.L., Antifungal susceptibility testing of yeast isolated from corneal infections (2003) Arq Bras Oftalmol, 66 (5), pp. 647-652Mattia, A., Cerniglia, C., Baines, J., Safety evaluation of certain food additives and contaminants Natamycin, , http://www.inchem.org/documents/jecfa/jecmono/v48je06.htm, Pimaricin WHO Food Additives Series: 48.Available fromTu, E.Y., McCartney, D.L., Beatty, R.F., Springer, K.L., Levy, J., Edward, D., Successful treatment of resistant ocular fusariosis with posaconazole (2007) Am J Ophthalmol, 143 (2), pp. 222-227. , SCH-56592Jones, D.B., Sexton, R., Rebell, G., Mycotic keratitis in South Florida: a review of thirty-nine cases (1970) Trans Ophthalmol Soc U K, 89, pp. 781-797Panda, A., Sharma, N., Das, G., Kumar, N., Satpathy, G., Mycotic keratitis in children: epidemiologic and microbiologic evaluation (1997) Cornea, 16 (3), pp. 295-299Rosa, R.H., Miller, D., Alfonso, E.C., The changing spectrum of fungal keratitis in south Florida (1994) Ophthalmology, 101 (6), pp. 1005-1013Oliveira, L.A., Takata, T.T., Shiguematsu, A.I., Júnior, M.L.A., Gompertz, O.F., Sousa, L.B., Mannis, M.J., Effect of topical 0.5% povidone-iodine compared to 5% natamycin in fungal keratitis caused by Fusarium solani in a rabbit model: a pilot study (2008) Arq Bras Oftalmol, 71 (6), pp. 860-864Prajna, N.V., Mascarenhas, J., Krishnan, T., Reddy, P.R., Prajna, L., Srinivasan, M., Comparison of natamycin and voriconazole for the treatment of fungal keratitis (2010) Arch Ophthalmol, 128 (6), pp. 672-678. , Comment in Arch Ophthalmol. 2011;129(6):814author reply 814-5Prajna, N.V., John, R.K., Nirmalan, P.K., Lalitha, P., Srinivasan, M., A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis (2003) Br J Ophthalmol, 87 (10), pp. 1235-1237Dursun, D., Fernandez, V., Miller, D., Alfonso, E.C., Advanced fusarium keratitis progressing to endophthalmitis (2003) Cornea, 22 (4), pp. 300-303Tanure, M.A., Cohen, E.J., Sudesh, S., Rapuano, C.J., Laibson, P.R., Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania (2000) Cornea, 19 (3), pp. 307-312Kalavathy, C.M., Parmar, P., Kaliamurthy, J., Philip, V.R., Ramalingam, M.D., Jesudasan, C.A., Thomas, P.A., Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungal keratitis (2005) Cornea, 24 (4), pp. 449-452Klont, R.R., Eggink, C.A., Rijs, A.J., Wesseling, P., Verweij, P.E., Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole (2005) Clin Infect Dis, 40 (12), pp. e110-2Lalitha, P., Shapiro, B.L., Srinivasan, M., Prajna, N.V., Acharya, N.R., Fothergill, A.W., Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis (2007) Arch Ophthalmol, 125 (6), pp. 789-793Li, L., Wang, Z., Li, R., Luo, S., Sun, X., In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients (2008) Am J Ophthalmol, 146 (5), pp. 724-728Xuguang, S., Zhixin, W., Zhiqun, W., Shiyun, L., Ran, L., Ocular fungal isolates and antifungal susceptibility in northern China (2007) Am J Ophthalmol, 143 (1), pp. 131-133Pearce, J.W., Giuliano, E.A., Moore, C.P., In vitro susceptibility patterns of Aspergillus and Fusarium species isolated from equine ulcerative keratomycosis cases in the midwestern and southern United States with inclusion of the new antifungal agent voriconazole (2009) Vet Ophthalmol, 12 (5), pp. 318-324Jones, D.B., Forster, F.K., Rebell, G., Fusarium solani keratitis treated with natamycin (pimaricin): eighteen consecutive cases (1972) Arch Ophthalmol, 88 (2), pp. 147-154Polack, F.M., Kaufman, H.E., Newmark, E., Keratomycosis.Medical and surgical treatment (1971) Arch Ophthalmol, 85 (4), pp. 410-416Amaral, V.C.S., Junior, N.G.P., Ketoconazole- and fluconazole-induced embryotoxicity and skeletal anomalies in wistar rats: a comparative study (2008) Braz Arch Biol Technol, 51 (6), pp. 1153-1161Sawyer, P.R., Brogden, R.N., Pinder, R.M., Speight, T.M., Avery, G.S., Miconazole: a review of its antifungal activity and therapeutic efficacy (1975) Drugs, 9 (6), pp. 406-423Coley, K.C., Crain, J.L., Miconazole-induced fatal dysrhythmia (1997) Pharmacotherapy, 17 (2), pp. 379-382Barasch, A., Griffin, A.V., Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials (2008) Future Microbiol, 3 (3), pp. 265-269Fothergill, A.W., Miconazole: a historical perspective (2006) Expert Rev Anti Infect Ther, 4 (2), pp. 171-175Kobayashi, D., Kondo, K., Uehara, N., Otokozawa, S., Tsuji, N., Yagihashi, A., Watanabe, N., Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect (2002) Antimicrob Agents Chemother, 46 (10), pp. 3113-3117Thevissen, K., Ayscough, K.R., Aerts, A.M., Du, W., De Brucker, K., Meert, E.M., Miconazole induces changes in actin cytoskeleton prior to reactive oxygen species induction in yeast (2007) J Biol Chem, 282 (30), pp. 21592-7Sud, I.J., Feingold, D.S., Mechanisms of action of the antimycotic imidazoles (1981) J Invest Dermatol, 76 (6), pp. 438-441Foster, C.S., Stefanyszyn, M., Intraocular penetration of miconazole in rabbits (1979) Arch Ophthalmol, 97 (9), pp. 1703-1706Mohan, M., Panda, A., Gupta, S.K., Management of human keratomycosis with miconazole (1989) Aust N Z J Ophthalmol, 17 (3), pp. 295-297Fitzsimons, R., Peters, A.L., Miconazole and ketoconazole as a satisfactory first-line treatment for keratomycosis (1986) Am J Ophthalmol, 101 (5), pp. 605-608Gupta, S.K., Efficacy of miconazole in experimental keratomycosis (1986) Aust N Z J Ophthalmol, 14 (4), pp. 373-376Foster, C.S., Miconazole therapy for keratomycosis (1981) Am J Ophthalmol, 91 (5), pp. 622-629Ishibashi, Y., Kaufman, H.E., The effects of subconjunctival miconazole in the treatment of experimental Candida keratitis in rabbits (1985) Arch Ophthalmol, 103 (10), pp. 1570-1573Thomas, P.A., Current perspectives on ophthalmic mycoses (2003) Clin Microbiol Rev, 16 (4), pp. 730-797Uchida, K., Abe, S., Yamaguchi, H., The postantifungal effect (PAFE) of itraconazole, in comparison with those of miconazole and fluconazole, on Candida Species (2006) Microbiol Immunol, 50 (9), pp. 679-685Heel, R.C., Brogden, R.N., Speight, T.M., Avery, G.S., Econazole: a review of its antifungal activity and therapeutic efficacy (1978) Drugs, 16 (3), pp. 177-201Mahashabde, S., Nahata, M.C., Shrivastava, U., A comparative study of anti-fungal drugs in mycotic corneal ulcer (1987) Indian J Ophthalmol, 35 (5-6), pp. 149-152Ishibashi, Y., Oral ketoconazole therapy for keratomycosis (1983) Am J Ophthalmol, 95 (3), pp. 342-345Thomas, P.A., Kalavathy, C.M., Abraham, D.J., Rajasekaran, J., Oral ketoconazole in Keratomycosis (1987) Indian J Ophthalmol, 35 (4), pp. 197-203Ishibashi, Y., Miconazole and ketoconazole as a satisfactory first-line treatment for keratomycosis (1986) Am J Ophthalmol, 102 (4), pp. 547-548Torres, M.A., Mohamed, J., Cavazos-Adame, H., Martinez, L.A., Topical ketoconazole for fungal keratitis (1985) Am J Ophthalmol, 100 (2), pp. 293-298Komadina, T.G., Wilkes, T.D., Shock, J.P., Ulmer, W.C., Jackson, J., Bradsher, R.W., Treatment of Aspergillus fumigatus keratitis in rabbits with oral and topical ketoconazole (1985) Am J Ophthalmol, 99 (4), pp. 476-479Singh, S.M., Khan, R., Sharma, S., Chatterjee, P.K., Clinical and experimental mycotic corneal ulcer caused by Aspergillus fumigatus and the effect of oral ketoconazole in the treatment (1989) Mycopathologia, 106 (3), pp. 133-141Marangon, F.B., Miller, D., Giaconi, J.A., Alfonso, E.C., In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens (2004) Am J Ophthalmol, 137 (5), pp. 820-825Rajasekaran, J., Thomas, P.A., Kalavathy, C.M., Joseph, P.C., Abraham, D.J., Itraconazole therapy for fungal keratitis (1987) Indian J Ophthalmol, 35 (5-6), pp. 157-160Abad, J.C., Foster, C.S., Fungal keratitis (1996) Int Ophthalmol Clin, 36 (3), pp. 1- 15. , ReviewKlotz, S.A., Zahid, M., Bartholomew, W.R., Revera, P.M., Butrus, S., Candida albicans keratitis treated successfully with itraconazole (1996) Cornea, 15 (1), pp. 102-104O'Day, D.M., Foulds, G., Williams, T.E., Robinson, R.D., Allen, R.H., Head, W.S., Ocular uptake of fluconazole following oral administration (1990) Arch Ophthalmol, 108 (7), pp. 1006-1008Thakar, M., Oral fluconazole therapy for keratomycosis (1994) Acta Ophthalmol (Copenh), 72 (6), pp. 765-767Urbak, S.F., Degn, T., Fluconazole in the management of fungal ocular infections (1994) Ophthalmologica, 208 (3), pp. 147-156Mahdy, R.A., Nada, W.M., Wageh, M.M., Kader, M.A., Saleh, M.M., Alswad, M.M., Assessment safety and efficacy of a combination therapy of topical amphotericin B and subconjunctival fluconazole for the treatment of fungal keratitis (2010) Cutan Ocul Toxicol, 29 (3), pp. 193-197Yilmaz, S., Maden, A., Severe fungal keratitis treated with subconjunctival fluconazole (2005) Am J Ophthalmol, 140 (3), pp. 454-458. , Comment in Am J Ophthalmol. 2006;141(4):783author reply 783-4Mahdy, R.A., Nada, W.M., Wageh, M.M., Topical amphotericin B and subconjunctival injection of fluconazole combination therapy versus topical amphotericin B monotherapy in treatment of keratomycosis (2010) J Ocul Pharmacol Ther, 26 (3), pp. 281-285Yee, R.W., Cheng, C.J., Meenakshi, S., Ludden, T.M., Wallace, J.E., Rinaldi, M.G., Ocular penetration and pharmacokinetics of topical fluconazole (1997) Cornea, 16 (1), pp. 64-71. , Comment in Cornea. 1997;16(6):700Avunduk, A.M., Beuerman, R.W., Warnel, E.D., Kaufman, H.E., Greer, D., Comparison of efficacy of topical and oral fluconazole treatment in experimental Aspergillus keratitis (2003) Curr Eye Res, 26 (2), pp. 113-117Dotto, P.F., Rodrigues, L.D., Fernandes, M.L.B., Figueira, B.B.D., Takahashi, W.Y., Carani, J.C., Serracarbassa, P.D., Uso do fluconazol endovenoso no tratamento da endoftalmite fúngica endógena: relato de caso (2005) Arq Bras Oftalmol, 68 (4), pp. 543-546Christmas, N.J., Smiddy, W.E., Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis (1996) Ophthalmic Surg Lasers, 27 (12), pp. 1012-1018Wellington, M., Gigliotti, F., Update on antifungal agents (2001) Pediatr Infect Dis J, 20 (10), pp. 993-995Hariprasad, S.M., Mieler, W.F., Lin, T.K., Sponsel, W.E., Graybill, J.R., Voriconazole in the treatment of fungal eye infections: a review of current literature (2008) Br J Ophthalmol, 92 (7), pp. 871-878Herbrecht, R., Denning, D.W., Patterson, T.F., Bennett, J.E., Greene, R.E., Oestmann, J.W., Kern, W.V., Pauw, P.B., Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis (2002) N Engl J Med, 347 (6), pp. 408- 15. , Comment in N Engl J Med. 2002;347(25):2080-1author reply 2080-1. N Engl J Med. 2002;347(25):2080-1author reply 2080-1. N Engl J Med. 2004;350(9):950-2Freda, R., Use of oral voriconazole as adjunctive treatment of severe cornea fungal infection: case report (2006) Arq Bras Oftalmol, 69 (3), pp. 431-434Hariprasad, S.M., Mieler, W.F., Holz, E.R., Gao, H., Kim, J.E., Chi, J., Prince, R.A., Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans (2004) Arch Ophthalmol, 122 (1), pp. 42-47Gao, H., Pennesi, M., Shah, K., Qiao, X., Hariprasad, S.M., Mieler, W.F., Safety of intravitreal voriconazole: electroretinographic and histopathologic studies (2003) Trans Am Ophthalmol Soc, 101, pp. 183-189. , discussion 189Anderson, K.L., Mitra, S., Salouti, R., Pham, T.A., Taylor, H.R., Fungal keratitis caused by Paecilomyces lilacinus associated with a retained intracorneal hair (2004) Cornea, 23 (5), pp. 516-521Bunya, V.Y., Hammersmith, K.M., Rapuano, C.J., Ayres, B.D., Cohen, E.J., Topical and oral voriconazole in the treatment of fungal keratitis (2007) Am J Ophthalmol, 143 (1), pp. 151-153Lee, S.J., Lee, J.J., Kim, S.D., Topical and oral voriconazole in the treatment of fungal keratitis (2009) Korean J Ophthalmol, 23 (1), pp. 46-48Nulens, E., Eggink, C., Rijs, A.J., Wesseling, P., Verweij, P.E., Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole (2003) J Clin Microbiol, 41 (5), pp. 2261-2264Polizzi, A., Siniscalchi, C., Mastromarino, A., Saccà, S.C., Effect of voriconazole on a corneal abscess caused by fusarium (2004) Acta Ophthalmol Scand, 82 (6), pp. 762-764Al-Badriyeh, D., Neoh, C.F., Stewart, K., Kong, D.C., Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis (2010) Clin Ophthalmol, 4, pp. 391-405Dupuis, A., Tournier, N., Moal, L.G., Venisse, N., Preparation and stability of voriconazole eye drop solution (2009) Antimicrob Agents Chemother, 53 (2), pp. 798-799Clode, A.B., Davis, J.L., Salmon, J., Michau, T.M., Gilger, B.C., Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses (2006) Am J Vet Res, 67 (2), pp. 296-301Prakash, G., Sharma, N., Goel, M., Titiyal, J.S., Vajpayee, R.B., Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis (2008) Am J Ophthalmol, 146 (1), pp. 56-59Siatiri, H., Daneshgar, F., Siatiri, N., Khodabande, A., The effects of intrastromal voriconazole injection and topical voriconazole in the treatment of recalcitrant Fusarium keratitis (2011) Cornea, 30 (8), pp. 872-875Sharma, N., Agarwal, P., Sinha, R., Titiyal, J.S., Velpandian, T., Vajpayee, R.B., Evaluation of intrastromal voriconazole injection in recalcitrant deep fungal keratitis: case series (2011) Br J Ophthalmol, 95 (12), pp. 1735-1737Giaconi, J.A., Marangon, F.B., Miller, D., Alfonso, E.C., Voriconazole and fungal keratitis: a report of two treatment failures (2006) J Ocul Pharmacol Ther, 22 (6), pp. 437-439Diekema, D.J., Messer, S.A., Hollis, R.J., Jones, R.N., Pfaller, M.A., Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi (2003) J Clin Microbiol, 41 (8), pp. 3623-3626Johnson, L.B., Kauffman, C.A., Voriconazole: a new triazole antifungal agent (2003) Clin Infect Dis, 36 (5), pp. 630-637Espinel-Ingroff, A., Boyle, K., Sheehan, D.J., In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature (2001) Mycopathologia, 150 (3), pp. 101-115Marco, F., Pfaller, M.A., Messer, S.A., Jones, R.N., Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi (1998) Med Mycol, 36 (6), pp. 433-436Ullmann, A.J., Cornely, O.A., Burchardt, A., Hachem, R., Kontoyiannis, D.P., Töpelt, K., Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection (2006) Antimicrob Agents Chemother, 50 (2), pp. 658-666Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M.J., Monzon, A., Rodriguez-Tudela, J.L., Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi (2006) Antimicrob Agents Chemother, 50 (3), pp. 917-921Torres, H.A., Hachem, R.Y., Chemaly, R

Forward pi^0 Production and Associated Transverse Energy Flow in Deep-Inelastic Scattering at HERA

Deep-inelastic positron-proton interactions at low values of Bjorken-x down to x \approx 4.10^-5 which give rise to high transverse momentum pi^0 mesons are studied with the H1 experiment at HERA. The inclusive cross section for pi^0 mesons produced at small angles with respect to the proton remnant (the forward region) is presented as a function of the transverse momentum and energy of the pi^0 and of the four-momentum transfer Q^2 and Bjorken-x. Measurements are also presented of the transverse energy flow in events containing a forward pi^0 meson. Hadronic final state calculations based on QCD models implementing different parton evolution schemes are confronted with the data.Comment: 27 pages, 8 figures and 3 table

Measurement of Leading Proton and Neutron Production in Deep Inelastic Scattering at HERA

Deep--inelastic scattering events with a leading baryon have been detected by the H1 experiment at HERA using a forward proton spectrometer and a forward neutron calorimeter. Semi--inclusive cross sections have been measured in the kinematic region 2 <= Q^2 <= 50 GeV^2, 6.10^-5 <= x <= 6.10^-3 and baryon p_T <= MeV, for events with a final state proton with energy 580 <= E' <= 740 GeV, or a neutron with energy E' >= 160 GeV. The measurements are used to test production models and factorization hypotheses. A Regge model of leading baryon production which consists of pion, pomeron and secondary reggeon exchanges gives an acceptable description of both semi-inclusive cross sections in the region 0.7 <= E'/E_p <= 0.9, where E_p is the proton beam energy. The leading neutron data are used to estimate for the first time the structure function of the pion at small Bjorken--x.Comment: 30 pages, 9 figures, 2 tables, submitted to Eur. Phys.

The blood metabolome of incident kidney cancer: A case-control study nested within the MetKid consortium.

BackgroundExcess bodyweight and related metabolic perturbations have been implicated in kidney cancer aetiology, but the specific molecular mechanisms underlying these relationships are poorly understood. In this study, we sought to identify circulating metabolites that predispose kidney cancer and to evaluate the extent to which they are influenced by body mass index (BMI).Methods and findingsWe assessed the association between circulating levels of 1,416 metabolites and incident kidney cancer using pre-diagnostic blood samples from up to 1,305 kidney cancer case-control pairs from 5 prospective cohort studies. Cases were diagnosed on average 8 years after blood collection. We found 25 metabolites robustly associated with kidney cancer risk. In particular, 14 glycerophospholipids (GPLs) were inversely associated with risk, including 8 phosphatidylcholines (PCs) and 2 plasmalogens. The PC with the strongest association was PC ae C34:3 with an odds ratio (OR) for 1 standard deviation (SD) increment of 0.75 (95% confidence interval [CI]: 0.68 to 0.83, p = 2.6 × 10-8). In contrast, 4 amino acids, including glutamate (OR for 1 SD = 1.39, 95% CI: 1.20 to 1.60, p = 1.6 × 10-5), were positively associated with risk. Adjusting for BMI partly attenuated the risk association for some-but not all-metabolites, whereas other known risk factors of kidney cancer, such as smoking and alcohol consumption, had minimal impact on the observed associations. A mendelian randomisation (MR) analysis of the influence of BMI on the blood metabolome highlighted that some metabolites associated with kidney cancer risk are influenced by BMI. Specifically, elevated BMI appeared to decrease levels of several GPLs that were also found inversely associated with kidney cancer risk (e.g., -0.17 SD change [ßBMI] in 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2) levels per SD change in BMI, p = 3.4 × 10-5). BMI was also associated with increased levels of glutamate (ßBMI: 0.12, p = 1.5 × 10-3). While our results were robust across the participating studies, they were limited to study participants of European descent, and it will, therefore, be important to evaluate if our findings can be generalised to populations with different genetic backgrounds.ConclusionsThis study suggests a potentially important role of the blood metabolome in kidney cancer aetiology by highlighting a wide range of metabolites associated with the risk of developing kidney cancer and the extent to which changes in levels of these metabolites are driven by BMI-the principal modifiable risk factor of kidney cancer

Prognostic significance of MRI-detected extramural venous invasion according to grade and response to neo-adjuvant treatment in locally advanced rectal cancer A national cohort study after radiologic training and reassessment

Background: Detection of grade 3–4 extra mural venous invasion (mrEMVI) on magnetic resonance imaging (MRI) is associated with an increased distant metastases (DM)-rate. This study aimed to determine the impact of different grades of mrEMVI and their disappearance after neoadjuvant therapy.Methods: A Dutch national retrospective cross-sectional study was conducted, including patients who underwent resection for rectal cancer in 2016 from 60/69 hospitals performing rectal surgery. Patients with a cT3-4 tumour ≤8 cm from the anorectal junction were selected and their MRI-scans were reassessed by trained abdominal radiologists. Positive mrEMVI grades (3 and 4) were analyzed in regard to 4-year local recurrence (LR), DM, disease-free survival (DFS) and overall survival (OS). Results: The 1213 included patients had a median follow-up of 48 months (IQR 30–54). Positive mrEMVI was present in 324 patients (27%); 161 had grade 3 and 163 had grade 4. A higher mrEMVI stage (grade 4 vs grade 3 vs no mrEMVI) increased LR-risk (21% vs 18% vs 7%, &lt;0.001) and DM-risk (49% vs 30% vs 21%, p &lt; 0.001) and decreased DFS (42% vs 55% vs 69%, p &lt; 0.001) and OS (62% vs 76% vs 81%, p &lt; 0.001), which remained independently associated in multivariable analysis. When mrEMVI had disappeared on restaging MRI, DM-rate was comparable to initial absence of mrEMVI (both 26%), whereas LR-rate remained high (22% vs 9%, p = 0.006). Conclusion: The negative oncological impact of mrEMVI on recurrence and survival rates was dependent on grading. Disappearance of mrEMVI on restaging MRI decreased the risk of DM, but not of LR.</p

Prognostic significance of MRI-detected extramural venous invasion according to grade and response to neo-adjuvant treatment in locally advanced rectal cancer A national cohort study after radiologic training and reassessment

Background: Detection of grade 3–4 extra mural venous invasion (mrEMVI) on magnetic resonance imaging (MRI) is associated with an increased distant metastases (DM)-rate. This study aimed to determine the impact of different grades of mrEMVI and their disappearance after neoadjuvant therapy.Methods: A Dutch national retrospective cross-sectional study was conducted, including patients who underwent resection for rectal cancer in 2016 from 60/69 hospitals performing rectal surgery. Patients with a cT3-4 tumour ≤8 cm from the anorectal junction were selected and their MRI-scans were reassessed by trained abdominal radiologists. Positive mrEMVI grades (3 and 4) were analyzed in regard to 4-year local recurrence (LR), DM, disease-free survival (DFS) and overall survival (OS). Results: The 1213 included patients had a median follow-up of 48 months (IQR 30–54). Positive mrEMVI was present in 324 patients (27%); 161 had grade 3 and 163 had grade 4. A higher mrEMVI stage (grade 4 vs grade 3 vs no mrEMVI) increased LR-risk (21% vs 18% vs 7%, &lt;0.001) and DM-risk (49% vs 30% vs 21%, p &lt; 0.001) and decreased DFS (42% vs 55% vs 69%, p &lt; 0.001) and OS (62% vs 76% vs 81%, p &lt; 0.001), which remained independently associated in multivariable analysis. When mrEMVI had disappeared on restaging MRI, DM-rate was comparable to initial absence of mrEMVI (both 26%), whereas LR-rate remained high (22% vs 9%, p = 0.006). Conclusion: The negative oncological impact of mrEMVI on recurrence and survival rates was dependent on grading. Disappearance of mrEMVI on restaging MRI decreased the risk of DM, but not of LR.</p

Impact of the new rectal cancer definition on multimodality treatment and interhospital variability:Results from a nationwide cross-sectional study

Aim: This study aimed to determine the consequences of the new definition of rectal cancer for decision-making in multidisciplinary team meetings (MDT). The new definition of rectal cancer, the lower border of the tumour is located below the sigmoid take-off (STO), was implemented in the Dutch guideline in 2019 after an international Delphi consensus meeting to reduce interhospital variations. Method: All patients with rectal cancer according to the local MDT, who underwent resection in 2016 in the Netherlands were eligible for this nationwide collaborative cross-sectional study. MRI-images were rereviewed, and the tumours were classified as above or on/below the STO. Results: This study registered 3107 of the eligible 3178 patients (98%), of which 2784 patients had an evaluable MRI. In 314 patients, the tumour was located above the STO (11%), with interhospital variation between 0% and 36%. Based on TN-stage, 175 reclassified patients with colon cancer (6%) would have received different treatment (e.g., omitting neoadjuvant radiotherapy, candidate for adjuvant chemotherapy). Tumour location above the STO was independently associated with lower risk of 4-year locoregional recurrence (HR 0.529; p = 0.030) and higher 4-year overall survival (HR 0.732; p = 0.037) compared to location under the STO. Conclusion: By using the STO, 11% of the prior MDT-based diagnosis of rectal cancer were redefined as sigmoid cancer, with potential implications for multimodality treatment and prognostic value. Given the substantial interhospital variation in proportion of redefined cancers, the use of the STO will contribute to standardisation and comparability of outcomes in both daily practice and trial settings.</p

Evaluation of National Surgical Practice for Lateral Lymph Nodes in Rectal Cancer in an Untrained Setting

Background: Involved lateral lymph nodes (LLNs) have been associated with increased local recurrence (LR) and ipsi-lateral LR (LLR) rates. However, consensus regarding the indication and type of surgical treatment for suspicious LLNs is lacking. This study evaluated the surgical treatment of LLNs in an untrained setting at a national level. Methods: Patients who underwent additional LLN surgery were selected from a national cross-sectional cohort study regarding patients undergoing rectal cancer surgery in 69 Dutch hospitals in 2016. LLN surgery consisted of either ‘node-picking’ (the removal of an individual LLN) or ‘partial regional node dissection’ (PRND; an incomplete resection of the LLN area). For all patients with primarily enlarged (≥7 mm) LLNs, those undergoing rectal surgery with an additional LLN procedure were compared to those undergoing only rectal resection. Results: Out of 3057 patients, 64 underwent additional LLN surgery, with 4-year LR and LLR rates of 26% and 15%, respectively. Forty-eight patients (75%) had enlarged LLNs, with corresponding recurrence rates of 26% and 19%, respectively. Node-picking (n = 40) resulted in a 20% 4-year LLR, and a 14% LLR after PRND (n = 8; p = 0.677). Multivariable analysis of 158 patients with enlarged LLNs undergoing additional LLN surgery (n = 48) or rectal resection alone (n = 110) showed no significant association of LLN surgery with 4-year LR or LLR, but suggested higher recurrence risks after LLN surgery (LR: hazard ratio [HR] 1.5, 95% confidence interval [CI] 0.7–3.2, p = 0.264; LLR: HR 1.9, 95% CI 0.2–2.5, p = 0.874). Conclusion: Evaluation of Dutch practice in 2016 revealed that approximately one-third of patients with primarily enlarged LLNs underwent surgical treatment, mostly consisting of node-picking. Recurrence rates were not significantly affected by LLN surgery, but did suggest worse outcomes. Outcomes of LLN surgery after adequate training requires further research.</p

Prognostic Implications of Lateral Lymph Nodes in Rectal Cancer:A Population-Based Cross-sectional Study with Standardized Radiological Evaluation after Dedicated Training

BACKGROUND: There is an ongoing discussion regarding the prognostic implications of the presence, short-axis diameter, and location of lateral lymph nodes. OBJECTIVE: To analyze lateral lymph node characteristics, the role of downsizing on restaging MRI, and associated local recurrence rates for patients with cT3-4 rectal cancer after MRI re-review and training. DESIGN: Retrospective population-based cross-sectional study. SETTINGS: This collaborative project was led by local investigators from surgery and radiology departments in 60 Dutch hospitals. PATIENTS: A total of 3057 patients underwent rectal cancer surgery in 2016: 1109 had a cT3-4 tumor located ≤8 cm from the anorectal junction, of whom 891 received neoadjuvant therapy. MAIN OUTCOME MEASURES: Local recurrence and (ipsi) lateral local recurrence rates. RESULTS: Re-review identified 314 patients (35%) with visible lateral lymph nodes. Of these, 30 patients had either only long-stretched obturator (n = 13) or external iliac (n = 17) nodes, and both did not lead to any lateral local recurrences. The presence of internal iliac/obturator lateral lymph nodes (n = 284) resulted in 4-year local recurrence and lateral local recurrence rates of 16.4% and 8.8%, respectively. Enlarged (≥7 mm) lateral lymph nodes (n = 122) resulted in higher 4-year local recurrence (20.8%, 13.1%, 0%; p &lt;.001) and lateral local recurrence (14.7%, 4.4%, 0%; p &lt; 0.001) rates compared to smaller and no lateral lymph nodes, respectively. Visible lateral lymph nodes (HR 1.8 [1.1-2.8]) and enlarged lateral lymph nodes (HR 1.9 [1.1-3.5]) were independently associated with local recurrence in multivariable analysis. Enlarged lateral lymph nodes with malignant features had higher 4-year lateral local recurrence rates of 17.0%. Downsizing had no impact on lateral local recurrence rates. Enlarged lateral lymph nodes were found to be associated with higher univariate 4-year distant metastasis rates (36.4% vs 24.4%; p = 0.021), but this was not significant in multivariable analyses (HR 1.3 [0.9-1.]) and did not worsen overall survival. LIMITATIONS: This study was limited by the retrospective design and total number of patients with lateral lymph nodes. CONCLUSIONS: The risk of lateral local recurrence due to (enlarged) lateral lymph nodes was confirmed, but without the prognostic impact of downsizing after neoadjuvant therapy. These results point toward the incorporation of primary lateral lymph node size into treatment planning. See Video Abstract.</p

First record of Rhabdoceras suessi (Ammonoidea, Late Triassic) from the Transylvanian Triassic Series of the Eastern Carpathians (Romania) and a review of its biochronology, paleobiogeography and paleoecology

Abstract The occurrence of the heteromorphic ammonoid Rhabdoceras suessi Hauer, 1860, is recorded for the first time in the Upper Triassic limestone of the Timon-Ciungi olistolith in the Rarău Syncline, Eastern Carpathians. A single specimen of Rhabdoceras suessi co-occurs with Monotis (Monotis) salinaria that constrains its occurrence here to the Upper Norian (Sevatian 1). It is the only known heteromorphic ammonoid in the Upper Triassic of the Romanian Carpathians. Rhabdoceras suessi is a cosmopolitan species widely recorded in low and mid-paleolatitude faunas. It ranges from the Late Norian to the Rhaetian and is suitable for high-resolution worldwide correlations only when it co-occurs with shorter-ranging choristoceratids, monotid bivalves, or the hydrozoan Heterastridium. Formerly considered as the index fossil for the Upper Norian (Sevatian) Suessi Zone, by the latest 1970s this species lost its key biochronologic status among Late Triassic ammonoids, and it generated a controversy in the 1980s concerning the status of the Rhaetian stage. New stratigraphic data from North America and Europe in the subsequent decades resulted in a revised ammonoid biostratigraphy for the uppermost Triassic, the Rhaetian being reinstalled as the topmost stage in the current standard timescale of the Triassic. The geographic distribution of Rhabdoceras is compiled from published worldwide records, and its paleobiogeography and paleoecology are discussed